Sernova Appoints CEO Jonathan Rigby As Interim Chair Amid Financing Talks And Executive Changes

Sernova Biotherapeutics, a regenerative medicine company developing its Cell Pouch platform to treat type 1 diabetes, announced that CEO Jonathan Rigby has been appointed as Interim Chair of the Board of Directors. Rigby steps into this role immediately and will serve until a new independent Chair is appointed. The company also reiterated that financing talks are ongoing with GoldTrack Ventures and representatives from the Kingdom of Saudi Arabia. 

“Sernova is making significant strides on multiple strategic and operational fronts. The recent release of encouraging clinical data, the formation of a world-class Clinical Advisory Board, and active investment discussions with multiple parties is encouraging. As we advance toward our goal of delivering a functional cure for type 1 diabetes, we remain focused on execution and creating long-term shareholder value,” said Jonathan Rigby, Interim Chair and Chief Executive Officer of Sernova. 

Sernova views the potential investment as a strategically important step and remains optimistic about forming a strong and promising partnership to support its long-term growth. Additionally, Sernova confirmed the departure of its Chief Business Officer, Dr. Modestus Obochi.